NovoCure Limited officer Christoph Brackmann filed a Form 144 notice of proposed sale of 7,343 common shares on November 9, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller: Christoph Brackmann, identified as an officer of NovoCure Limited.
  • Shares proposed for sale: 7,343 common shares, with an aggregate market value of $94,445.67.
  • Shares outstanding: 116,915,959 common shares reported outstanding at the time of filing.
  • Acquisition date: The 7,343 shares were acquired on November 4, 2026, as restricted stock from the issuer.
  • Approximate date of sale: November 9, 2026, on NASDAQ.
  • Prior sales: No securities of the issuer were sold by the filing person during the past three months.

Brackmann's Proposed Rule 144 Sale of NovoCure Restricted Stock

According to the filing, Christoph Brackmann, an officer of NovoCure Limited (NASDAQ:NVCR), submitted a Form 144 notice disclosing a proposed sale of 7,343 common shares. The aggregate market value of the shares to be sold is listed as $94,445.67, and the total number of common shares outstanding is reported as 116,915,959.

The filing discloses that the shares to be sold were acquired on November 4, 2026, through a restricted stock transaction from the issuer, NovoCure Limited. The nature of payment is listed as "Not Applicable." The proposed broker for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with the approximate date of sale listed as November 9, 2026.

The filing notes that Brackmann reported no sales of NovoCure securities during the three months preceding this notice. By signing the Form 144, the filing person represented that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the form's attestation language.

What Was Disclosed

A Form 144 notice was filed on November 9, 2026, by NovoCure officer Christoph Brackmann, covering a proposed sale of 7,343 common shares acquired as restricted stock on November 4, 2026, with an aggregate market value of $94,445.67.